Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization-Reference-Cited by-同舟云学术

Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization

Published:2013-01-22 Issue:2 Volume:90 Page:142-150
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Drucker Aaron M.,Wu Shenhong¹,Busam Klaus J.²,Berman Ellin³,Amitay-Laish Iris⁴,Lacouture Mario E.⁵

Affiliation:

1. Division of Hematology and Medical Oncology; Stony Brook University Cancer Center

2. Dermatopathology Service; Department of Pathology; Memorial Sloan-Kettering Cancer Center

3. Leukemia Service; Department of Medicine; Memorial Sloan-Kettering Cancer Center

4. Department of Dermatology; Rabin Medical Center; Beilinson Hospital; Petach Tikva; Israel

5. Dermatology Service; Department of Medicine; Memorial Sloan-Kettering Cancer Center

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12052/fullpdf

Reference39 articles.

1. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia;le Coutre;Blood,2008

2. Efficacy of frontline nilotinib therapy in patients (pts) with newly diagnosed philadelphia chromosome (ph)-positive chronic myeloid leukemia in early chronic phase (CML-CP);Quintas-Cardama;ASH Ann Meeting Abstr,2011

3. Phase II study of dasatinib in philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis;Verstovsek;Clin Cancer Res,2008

4. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia;Cortes;J Clin Oncol,2010

5. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results;Kantarjian;Blood,2011

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second-generation Tyrosine Kinase Inhibitors Nilotinib- and Dasatinib-induced Keratosis Pilaris: A Case Report and Review of the Literature;Journal of Dermatology and Dermatologic Surgery;2024-01

2. Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib;Journal of Clinical Medicine;2023-12-20

3. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis;Acta Oncologica;2023-10-03

4. Rash with different types of BCR-ABL inhibitors in chronic myelogenous leukemia: a systematic review and meta-analysis;Future Oncology;2023-06

5. Screening and Activity Evaluation of Novel BCR-ABL/T315I Tyrosine Kinase Inhibitors;Current Medicinal Chemistry;2023-05-19